Dr. Robert Berman

Dr. Robert Berman first discovered the antidepressant effects of ketamine in humans alongside Dr John Krystal in 1990s at Yale. For over 20 years he has worked within the industry, first at Pfizer and then Bristol-Myers Squibb in clinical development roles, including leading the program for aripiprazole in depression, for which he developed novel clinical trial design that achieved three out of three highly statistically significant trials. In 2013, Rob co-founded Biohaven Pharmaceuticals (NYSE:BHVN) and was Chief Medical Officer until 2019.

Read More
Chief Medical Officer Shahzaib Ali Chief Medical Officer Shahzaib Ali

Dr. David Hough

David Hough, MD previously served as Chief Medical Officer at Freedom Biosciences. Prior to joining Freedom, Dr. Hough spent 17 years  in various leadership roles at Janssen Research and Development, LLC (a Johnson & Johnson company). Most recently, he was the leader of the compound development team working on Spravato (esketamine).

Read More
Shahzaib Ali Shahzaib Ali

Dr. Alex Kwan

Dr. Alex Kwan is a neuroscientist whose work is focused on the neurobiology of antidepressants. He is known for using sophisticated optical imaging methods to show how drugs such as ketamine and psilocybin modify the structure and function of brain circuitry. His research has been published in top peer-reviewed journals including Nature Neuroscience, Neuron, and Biological Psychiatry. He has a Ph.D. in Applied Physics from Cornell University and is currently an Associate Professor in the Meinig School of Biomedical Engineering at Cornell University.

Read More